Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg)

Olmedo, L; Calvet, X; Gené, E; Bordin, DS; Voynovan, I; Castro-Fernandez, M; Pabón-Carrasco, M; Keco-Huerga, A; Perez-Aisa, A; Lucendo, AJ; Rodrigo, L; Sarsenbaeva, AS; Khlinov, IB; Fadieienko, G; Zaytsev, O; Lanas, A; Martínez-Domínguez, SJ; Alfaro, E; Jonaitis, L; Núñez, O; Pellicano, R; Hernández, L; Gridnyev, O; Kupcinskas, J; Gasbarrini, A; Boltin, D; Niv, Y; Babayeva, G; Marcos-Pinto, R; Tepes, B; Venerito, M; Papp, V; Lerang, F; Leja, M; Phull, PS; Marlicz, W; Doulberis, M; Smith, SM; Milivojevic, V; Kunovsky, L; Mestrovic, A; Matysiak-Budnik, T; Simsek, H; Cano-Català, A; Puig, I; Moreira, L; Parra, P; Nyssen, OP; Megraud, F; O'Morain, C; Gisbert, JP

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg)

Background Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance.Objective To describe the time trends of use, eff...

Descripción completa

Detalles Bibliográficos
Autores:	Olmedo, L, Calvet, X, Gené, E, Bordin, DS, Voynovan, I, Castro-Fernandez, M, Pabón-Carrasco, M, Keco-Huerga, A, Perez-Aisa, A, Lucendo, AJ, Rodrigo, L, Sarsenbaeva, AS, Khlinov, IB, Fadieienko, G, Zaytsev, O, Lanas, A, Martínez-Domínguez, SJ, Alfaro, E, Jonaitis, L, Núñez, O, Pellicano, R, Hernández, L, Gridnyev, O, Kupcinskas, J, Gasbarrini, A, Boltin, D, Niv, Y, Babayeva, G, Marcos-Pinto, R, Tepes, B, Venerito, M, Papp, V, Lerang, F, Leja, M, Phull, PS, Marlicz, W, Doulberis, M, Smith, SM, Milivojevic, V, Kunovsky, L, Mestrovic, A, Matysiak-Budnik, T, Simsek, H, Cano-Català, A, Puig, I, Moreira, L, Parra, P, Nyssen, OP, Megraud, F, O'Morain, C, Gisbert, JP
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2024
País:	España
Institución:	Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:	oai:i3pt.fundanetsuite.com:p5331
Acceso en línea:	https://i3pt.portalinvestigacion.com/publicaciones/5331 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85210910124&doi=10.1136%2Fgutjnl-2024-332804&partnerID=40&md5=d873cd12c26a015cd4932639a4b85808
Access Level:	acceso abierto
Palabra clave:	HELICOBACTER PYLORI - TREATMENT ANTIBIOTIC THERAPY HELICOBACTER THERAPY

id	ES_71a90b2e5cecd79aad8544f2247a55a0
oai_identifier_str	oai:i3pt.fundanetsuite.com:p5331
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)Olmedo, LCalvet, XGené, EBordin, DSVoynovan, ICastro-Fernandez, MPabón-Carrasco, MKeco-Huerga, APerez-Aisa, ALucendo, AJRodrigo, LSarsenbaeva, ASKhlinov, IBFadieienko, GZaytsev, OLanas, AMartínez-Domínguez, SJAlfaro, EJonaitis, LNúñez, OPellicano, RHernández, LGridnyev, OKupcinskas, JGasbarrini, ABoltin, DNiv, YBabayeva, GMarcos-Pinto, RTepes, BVenerito, MPapp, VLerang, FLeja, MPhull, PSMarlicz, WDoulberis, MSmith, SMMilivojevic, VKunovsky, LMestrovic, AMatysiak-Budnik, TSimsek, HCano-Català, APuig, IMoreira, LParra, PNyssen, OPMegraud, FO'Morain, CGisbert, JPHELICOBACTER PYLORI - TREATMENTANTIBIOTIC THERAPYHELICOBACTER THERAPYBackground Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance.Objective To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg).Design Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success.Results Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT-containing bismuth, metronidazole and tetracycline-plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness.Conclusion The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness.Trial registration number NCT02328131.BMJ PUBLISHING GROUP2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/5331https://www.scopus.com/inward/record.uri?eid=2-s2.0-85210910124&doi=10.1136%2Fgutjnl-2024-332804&partnerID=40&md5=d873cd12c26a015cd4932639a4b85808GUTISSN: 00175749ISSNe: 14683288reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p53312026-06-21T15:30:37Z
dc.title.none.fl_str_mv	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)
title	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)
spellingShingle	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg) Olmedo, L HELICOBACTER PYLORI - TREATMENT ANTIBIOTIC THERAPY HELICOBACTER THERAPY
title_short	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)
title_full	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)
title_fullStr	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)
title_full_unstemmed	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)
title_sort	Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)
dc.creator.none.fl_str_mv	Olmedo, L Calvet, X Gené, E Bordin, DS Voynovan, I Castro-Fernandez, M Pabón-Carrasco, M Keco-Huerga, A Perez-Aisa, A Lucendo, AJ Rodrigo, L Sarsenbaeva, AS Khlinov, IB Fadieienko, G Zaytsev, O Lanas, A Martínez-Domínguez, SJ Alfaro, E Jonaitis, L Núñez, O Pellicano, R Hernández, L Gridnyev, O Kupcinskas, J Gasbarrini, A Boltin, D Niv, Y Babayeva, G Marcos-Pinto, R Tepes, B Venerito, M Papp, V Lerang, F Leja, M Phull, PS Marlicz, W Doulberis, M Smith, SM Milivojevic, V Kunovsky, L Mestrovic, A Matysiak-Budnik, T Simsek, H Cano-Català, A Puig, I Moreira, L Parra, P Nyssen, OP Megraud, F O'Morain, C Gisbert, JP
author	Olmedo, L
author_facet	Olmedo, L Calvet, X Gené, E Bordin, DS Voynovan, I Castro-Fernandez, M Pabón-Carrasco, M Keco-Huerga, A Perez-Aisa, A Lucendo, AJ Rodrigo, L Sarsenbaeva, AS Khlinov, IB Fadieienko, G Zaytsev, O Lanas, A Martínez-Domínguez, SJ Alfaro, E Jonaitis, L Núñez, O Pellicano, R Hernández, L Gridnyev, O Kupcinskas, J Gasbarrini, A Boltin, D Niv, Y Babayeva, G Marcos-Pinto, R Tepes, B Venerito, M Papp, V Lerang, F Leja, M Phull, PS Marlicz, W Doulberis, M Smith, SM Milivojevic, V Kunovsky, L Mestrovic, A Matysiak-Budnik, T Simsek, H Cano-Català, A Puig, I Moreira, L Parra, P Nyssen, OP Megraud, F O'Morain, C Gisbert, JP
author_role	author
author2	Calvet, X Gené, E Bordin, DS Voynovan, I Castro-Fernandez, M Pabón-Carrasco, M Keco-Huerga, A Perez-Aisa, A Lucendo, AJ Rodrigo, L Sarsenbaeva, AS Khlinov, IB Fadieienko, G Zaytsev, O Lanas, A Martínez-Domínguez, SJ Alfaro, E Jonaitis, L Núñez, O Pellicano, R Hernández, L Gridnyev, O Kupcinskas, J Gasbarrini, A Boltin, D Niv, Y Babayeva, G Marcos-Pinto, R Tepes, B Venerito, M Papp, V Lerang, F Leja, M Phull, PS Marlicz, W Doulberis, M Smith, SM Milivojevic, V Kunovsky, L Mestrovic, A Matysiak-Budnik, T Simsek, H Cano-Català, A Puig, I Moreira, L Parra, P Nyssen, OP Megraud, F O'Morain, C Gisbert, JP
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	HELICOBACTER PYLORI - TREATMENT ANTIBIOTIC THERAPY HELICOBACTER THERAPY
topic	HELICOBACTER PYLORI - TREATMENT ANTIBIOTIC THERAPY HELICOBACTER THERAPY
description	Background Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance.Objective To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg).Design Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success.Results Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT-containing bismuth, metronidazole and tetracycline-plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness.Conclusion The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness.Trial registration number NCT02328131.
publishDate	2024
dc.date.none.fl_str_mv	2024
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://i3pt.portalinvestigacion.com/publicaciones/5331 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85210910124&doi=10.1136%2Fgutjnl-2024-332804&partnerID=40&md5=d873cd12c26a015cd4932639a4b85808
url	https://i3pt.portalinvestigacion.com/publicaciones/5331 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85210910124&doi=10.1136%2Fgutjnl-2024-332804&partnerID=40&md5=d873cd12c26a015cd4932639a4b85808
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	BMJ PUBLISHING GROUP
publisher.none.fl_str_mv	BMJ PUBLISHING GROUP
dc.source.none.fl_str_mv	GUT ISSN: 00175749 ISSNe: 14683288 reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str	Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869410668757647360
score	15,81155

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)

Similares en LA Referencia